1. Home
  2. NWGL vs KPRX Comparison

NWGL vs KPRX Comparison

Compare NWGL & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nature Wood Group Limited

NWGL

Nature Wood Group Limited

HOLD

Current Price

$0.25

Market Cap

12.1M

Sector

N/A

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$2.66

Market Cap

10.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NWGL
KPRX
Founded
2008
1998
Country
Macau
United States
Employees
N/A
13
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.1M
10.7M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
NWGL
KPRX
Price
$0.25
$2.66
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
580.7K
25.8K
Earning Date
05-21-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$1.76
52 Week High
$2.55
$3.29

Technical Indicators

Market Signals
Indicator
NWGL
KPRX
Relative Strength Index (RSI) 19.31 54.20
Support Level N/A $2.65
Resistance Level $1.46 $2.91
Average True Range (ATR) 0.10 0.13
MACD -0.05 -0.01
Stochastic Oscillator 4.19 50.00

Price Performance

Historical Comparison
NWGL
KPRX

About NWGL Nature Wood Group Limited

CL Workshop Group Ltd, formerly Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: